IP Library Granted Patent US 9,051,371
Granted Patent B2
US 9,051,371 · App. 14/215,556 · Granted Jun 9, 2015

Human CDR-grafted antibody and antibody fragment thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,371
App. No.
14/215,556
Granted
Jun 9, 2015
Kind
B2
Abstract

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Claims (5)

1. A method for treating cancer in a patient, said method comprising administering to a patient in need thereof an effective amount of a human CDR-grafted antibody or antibody fragment thereof which reacts with an extracellular region of human CC chemokine receptor 4 (CCR4),

wherein the cancer cells of said cancer express CCR4, and wherein the antibody or antibody fragment comprises an antibody heavy chain (H chain) variable region (V region) comprising SEQ ID NO: 4, 9, 10, 11, 38, 39, 40 or 41; and an antibody light chain (L chain) V region comprising SEQ ID NO: 14.

2. The method according to claim 1 , wherein the human CDR-grafted antibody or antibody fragment thereof comprises an antibody heavy chain (H chain) variable region (V region) comprising SEQ ID NO: 9 or 10; and an antibody light chain (L chain) V region comprising SEQ ID NO: 14.

3. The method according to claim 1 , wherein the cancer is a blood cancer.

4. The method according to claim 3 , wherein the blood cancer is a leukemia or a lymphoma.

Assignments (1)
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →